HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Senate Wants PFAS Banned From Cosmetics. Should FDA Have A Say?

Executive Summary

Per- and polyfluoroalkyl substances are unpopular, sure. But there are thousands of PFAS with dissimilar safety profiles that merit US FDA review ahead of a blanket ban in cosmetic products, industry says.

You may also be interested in...



Two ‘Hot Buttons’ Right Now In Product Testing: Benzene In Sunscreens, PFAS In Cosmetics

Craig Weiss, co-CEO and president of CPT Labs, discusses recent reports driving interest in testing for benzene and PFAS in sunscreens and cosmetic products.

US Cosmetics Modernization Bill Relaunched, Now With Fragrance Allergen Labeling, PFAS Ban

The Personal Care Products Safety Act was reintroduced in the US Senate on 17 June with industry support including leading brands at big-name multinationals. The latest “Feinstein bill” for modernizing US cosmetics regulations purports to strengthen counterfeit product protections while floating additional requirements for fragrance allergen labeling and banning intentionally added PFAS.

US FDA Addresses PFAS In Cosmetics, Aiming To Close Data Gaps

Use of per- and polyfluoroalkyl substances in cosmetic products appears to be declining, based on voluntary industry registrations with the US Food and Drug Administration. NGOs are gunning for PFAS' elimination, and the FDA says available data have yet to give a complete safety picture for PFAS used intentionally in cosmetics or present as impurities.

Related Content

Topics

UsernamePublicRestriction

Register

RS151451

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel